188results about How to "Effective hemostasis" patented technology

The invention relates to the adhesion of platelet GpIbα to strand β3 of domain A1 of von Willebrand factor (vWF), the strand β3 comprising amino acid residues at amino acid position 560-566 and/or a functional part or equivalent thereof, the platelet GpIbα, the GpIbα region comprising an amino acid sequence corresponding to a beta-switch loop of platelet GpIbα, comprising amino acid residues at amino acid position 227-242 and/or a functional part or equivalent thereof. The invention provides a method of interfering with adhesion of blood platelets to vWF that includes modulating adhesion. The invention further provides proteinaceous compounds, antibodies, medicaments and pharmaceutical compositions to that end. The invention also provides means and methods to increase platelet adhesion by topical application of a compound increasing platelet adhesion.

For defects that existing hemostasis research and products cannot intelligently perform self-propelling or cannot be driven to forward deep in the wound under the action of external field force, the invention provides a preparation method for a janus structure based rapid hemostatic agent having a directional propulsion function. The preparation method includes performing esterification on microporous starch to unidirectionally grow calcium carbonate particles so as to obtain esterified microporous starch/calcium carbonate Janus particles; fixedly assembling thrombin on the surfaces of the esterified microporous starch/calcium carbonate Janus particles to obtain esterified microporous starch/calcium carbonate Janus particles assembled with the thrombin; mixing the esterified microporous starch/calcium carbonate Janus particles assembled with the thrombin and protonated tranexamic acid powder so as to obtain the janus structure based rapid hemostatic agent having a directional propulsion function. Through the formation of the biphasic heterogeneous Janus structure, the unidirectional and intelligent self-propulsion of hemostatic starch can be realized by cooperating with the protonated tranexamic acid, so that rapid three-dimensional hemostasis on deep wounds, penetrating wounds and irregular wounds such as aortic / venous rupture can be realized.

It is disclosed herein that protein C functions as a hemostatic agent. Thus, provided is a method of preventing, treating or ameliorating abnormal bleeding in a subject, comprising administering to the subject a protein C polypeptide or polynucleotide. Abnormal bleeding can result from a bleeding disorder, such as hemophilia or a platelet disorder, or from a bleeding episode, such as from a traumatic injury.

The invention discloses an injectable type self-healing hemostatic material as well as a preparation method and application thereof. The injectable type self-healing hemostatic material is obtained by self-assembling macromolecular microgel particles with surface charges through electrostatic interaction between the particles or the particles and macromolecules. The electrostatic action between the microgel particles or the particles and the macromolecules is physical crosslinking and has reversibility, so the hemostatic material prepared by the method has high injectability, self-healing capability and high mechanical strength, does not need to introduce chemical crosslinking reaction in the injection and solidification process, is different from chemical macromolecules, does not introduce a micromolecular crosslinking agent, has high biocompatibility, can be degraded and absorbed, does not have toxic or side effects, has high safety and makes wide application in the field of biomedicine possible.

Hemostatic devices and methods of making same are disclosed. Disclosed hemostatic devices include biocompatible non-oxidized regenerated cellulose. The disclosed hemostatic devices are effective in providing and maintaining hemostasis in cases of moderate to severe bleeding caused by non-compressional and/or non-tourniquetable injuries, among other things. The disclosed methods enable manufacture of a bioabsorbable, biocompatible, biodegradable carboxylmethyl cellulose having high stability and high adherence.

The invention discloses a preparation method of a hemostatic sponge, comprising the following steps: (1) dispersing oxidized cellulose powder into water to obtain 0.1-2.0wt% of oxidized cellulose dispersion, and then homogenizing the oxidized cellulose dispersion under high pressure to obtain a nanooxidized cellulose suspension; (2) injecting the nanooxidized cellulose suspension into a mold, performing 1 to 7 times of freeze-thaw cycles to obtain nanocellulose hydrogel, freezing the nanocellulose hydrogel for sizing, and then drying to obtain the hemostatic sponge; wherein one freeze-thaw process is: freezing for 8-16 h at -40 to -18 DEG C, and then unfreezing for 8-16 h at 4-25 DEG C. The invention also provides the hemostatic sponge prepared by the preparation method. The hemostatic sponge has high carboxyl content, high porosity and water absorption capacity, and can quickly absorb excess blood on the wound surface to achieve effective hemostasis.

The invention relates to the field of animal medicines, and particularly provides a Chinese medicine composition for stopping bleeding of sawing antler, a preparation method and application thereof. The Chinese medicine composition for stopping bleeding of sawing antler is mainly prepared from the following various raw materials in parts by mass: 32 to 37 parts of herba agrimoniae, 17 to 22 partsof rhizoma bletillae, 7 to 12 parts of radix notoginseng, 7 to 12 parts of Chinese arborvitae twig, 7 to 12 parts of pollen typhae, 7 to 12 parts of radix sanguisorbae and 4 to 6 parts of camphol. According to the Chinese medicine composition for stopping bleeding of sawing antler, rich traditional Chinese medicine resources and the characteristics of easiness for availability of the traditional Chinese medicines, low cost, greenness, no residues and the like are utilized, through a traditional theory of traditional Chinese medicine, rules of assistance and guide of monarch and minister medicines, dialectical treatment and mutual generation and restriction are conformed, and the characteristics of variety of the traditional herbal medicine components and complexity of the functions are used, and the compatibility is reasonable, so that the obtained Chinese medicine composition for stopping bleeding of sawing antler has the effects of quickly stopping bleeding and resisting bacteria andeliminating inflammation and also no side effect.

The invention discloses a collagen aggregate based flocculent antibacterial hemostatic material and a preparation method thereof. The preparation method is characterized by comprising steps as follows: DCMC (dialdehyde carboxymethyl cellulose) and silver nitrate are blended, a mixed solution containing nano-silver is prepared through redox reaction, then certain amount of collagen aggregate and certain amount of polyvinylpyrrolidone are dissolved in the mixed solution sequentially, the mixture is subjected to processes including gradient dilution, dealcoholization, vacuum drying, impregnation, freeze-drying, moderate grinding, sterilization and the like, and the collagen aggregate based flocculent antibacterial hemostatic material is obtained finally. The material adopts the collagen aggregate more similar to a natural tissue collagen structure, and compared with common collagen materials, the prepared flocculent hemostatic material has excellent physical and chemical properties and biological properties such as structural stability, mechanical property, biological degradability, biocompatibility and the like, can promote wound healing and repair, has broad-spectrum antibacterial/antimicrobial activity of the nano-silver, has large contact surface with the wound surface, is high in hydrophilia and stickiness and can be used for hemostasis repair of body surface wound and general civil hemostasis emergency.

The invention discloses a pit-hole composite micro-nano-structure polysaccharide microsphere and a preparation method. The preparation method comprises the following steps: (1) preparing a polysaccharide water solution; (2) adding an emulsifying agent into an oil phase so as to prepare the oil phase containing the emulsifying agent, dropwise adding the polysaccharide water solution into the oil phase containing the emulsifying agent, and stirring for emulsification, so as to obtain a uniform emulsion; (3) dissolving a polyvalent metal cross-linking agent into ultrapure water to prepare a cross-linking agent water solution, dropwise adding the cross-linking agent water solution into the uniform emulsion; and (4) adding n-hexane or petroleum ether into liquid obtained in the step (3), standing until the solution is layered, pouring out an upper oil phase layer, remaining a water phase, cleaning the water phase, and carrying out freeze-drying, so as to obtain the pit-hole composite micro-nano-structure polysaccharide microsphere. The surface of the microsphere is provided with nano-scale pits, and nano-scale fine holes are formed in the surfaces of the pits; the microsphere is uniformin particle size distribution, high in porosity and water absorption rate and strong in adsorbability; and the microsphere has good biocompatibility, and hemostasis can be effectively finished within20s-50s.

The invention provides a preparation method of a composite artificial bone material. The preparation method includes steps: (1) dissolving PLGA into an organic solvent, adding nano hydroxyapatite and beta-tricalcium phosphate, and well mixing to obtain 3D printing ink; (2) subjecting the 3D printing ink to low-temperature deposition printing by 3D printing equipment, and performing freeze drying to obtain a porous bone scaffold; (3) performing negative-pressure pouring of modified starch solution into the porous bone scaffold, and carrying out freeze drying to obtain the composite artificial bone material; (4) subjecting the composite artificial bone material to irradiation sterilization to obtain an artificial bone finished product. The composite artificial bone material is prepared from PLGA, nano hydroxyapatite, beta-tricalcium phosphate and modified starch by compounding, and the modified starch is capable of quickly and effectively stopping bleeding in a bone surgery process and also promoting osteoblast maturation and differentiation.

The invention aims to provide fiber suitable for clinical application, in particular to the application of hemostasis, scalding, chronic wound treatment and others. The invention is a hemostatic material, wherein the hemostatic material includes fiber, and the material is possessed of biodegradability; the hemostatic material is characterized in that the fiber includes a polymer expressed by the following structural formula: FORMULA, wherein R is at least one of groups consisting of -NH2, -CH2CH20H, -OCH2CH2CH2OH, -OH, -ONa, -OK, -OCa; m, n and p respectively represent the quantity percent of corresponding repeat unit in the polymer molecule and can meet the following relationship formula: m+n+p=1, p/(m+n+p)=0.05-0.30; the degree of substitution D is defined as m/(m+n+p), the total degree of substitution of fiber is defined as Ds, and the degree of substitution of polymer at the center of the fiber cross section is defined as D0; when the degree of substitution of the edge of the fiber cross section is defined as D, the following relationship formula can be satisfied: Ds=0.09-0.8, Do/D=0-0.7.

The present invention relates to a haemostatic bio-material composition and method for achieving hemostasis. The method for providing hemostasis generally comprises: supplying a dry potassium phosphate based hemostat mixture comprising: monobasic potassium phosphate, a metal oxide, and a tertiary calcium phosphate, wherein the weight percent ratio of monobasic potassium phosphate to metal oxide is between about 3:1 and 1:1; mixing the dry potassium phosphate based hemostat mixture with an aqueous solution forming an activated hemostat slurry; applying an hemostasis-promoting amount of the activated potassium phosphate based hemostat slurry to a site of bleeding; wherein the site of bleeding is in, on, or proximate to bone.